NCT05873712View on ClinicalTrials.gov

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Transformed Non-Hodgkin LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaRefractory Transformed
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Biopsy

Undergo BM biopsy

PROCEDURE

Computed Tomography

Undergo CT and/or PET/CT

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Given IV

BIOLOGICAL

Lisocabtagene Maraleucel

Given IV

PROCEDURE

Lymph Node Biopsy

Undergo lymph node biopsy

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Zanubrutinib

Given PO

Trial Locations (2)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

BeiGene USA, Inc.

INDUSTRY

lead

Aseel Alsouqi

OTHER